Welcome to our dedicated page for Applied DNA Sciences news (Ticker: APDN), a resource for investors and traders seeking the latest updates and insights on Applied DNA Sciences stock.
Applied DNA Sciences, Inc. (NASDAQ: APDN) is a biotechnology company pioneering advanced DNA-based technologies to safeguard assets and enhance industrial and healthcare applications. Headquartered in Stony Brook, NY, Applied DNA leverages Polymerase Chain Reaction (PCR) to produce and detect DNA and RNA, operating in three key segments: Therapeutic DNA Production Services, MDx Testing Services, and DNA Tagging and Security Products and Services.
In the Therapeutic DNA Production Services segment, Applied DNA produces synthetic DNA for nucleic acid-based therapeutics. With the acquisition of Spindle Biotech, the company has expanded its portfolio to include a proprietary RNA polymerase (RNAP) for mRNA therapeutics manufacturing. The recent contract with HDT Bio under the 'Project NextGen: Enabler' award aims to expedite mRNA vaccine production, highlighting the company's commitment to rapid-response medical solutions.
The MDx Testing Services segment, which includes clinical molecular diagnostic and genetic testing services, significantly contributes to the company's revenue. Applied DNA's innovative Linea™ IVT platform, designed to produce high-fidelity mRNA with reduced contamination, is a game-changer in molecular diagnostics.
Through the DNA Tagging and Security Products and Services segment, the company offers solutions under the brands Applied DNA Sciences, SigNature®, SigNature® T, fiberTyping, and SigNify®, providing robust anti-counterfeiting and product authentication services. These services are essential for supply chain security across various industries, including textiles and pharmaceuticals.
Recent achievements include closing a $12 million public offering to fund the development of DNA production services and the successful reverse stock split to comply with Nasdaq's minimum bid price requirements. Additionally, Applied DNA received a Notice of Allowance from the USPTO for a patent on its Linea™ RNAP, solidifying its intellectual property portfolio and extending patent protection into 2041.
Applied DNA remains dedicated to advancing DNA technology to meet the world’s evolving needs in healthcare, supply chain security, and beyond. For more information, visit their website at www.adnas.com and follow them on social media for the latest updates.
Applied DNA Sciences (NASDAQ: APDN) has secured approximately $3.6 million in net proceeds after an institutional investor exercised Series B warrants. These warrants were part of a public offering that concluded on August 8, 2022. Each warrant allows the purchase of one share at a price of $4.00 until September 8, 2023. There are currently 2.1 million Series B warrants outstanding, alongside 3 million Series A warrants that remain unexercised until August 9, 2027.
Applied DNA Sciences (NASDAQ: APDN) announced a conference call to discuss third-quarter fiscal results on August 11, 2022, at 4:30 p.m. ET. The call will be hosted by CEO Dr. James A. Hayward and CFO Beth Jantzen. Interested participants can access the call by dialing the provided numbers and are encouraged to connect through the company’s website for the webcast and presentation slides. Applied DNA is focused on developing PCR-based technologies for DNA production and detection across various markets.
Applied DNA Sciences has completed a public offering of 3,000,000 shares at $4.00 each, generating approximately $12 million in gross proceeds. The offering includes Series A and Series B warrants for additional shares, both exercisable at $4.00. H.C. Wainwright & Co. served as the placement agent. The company operates in DNA production and detection technologies, addressing therapeutic, diagnostic, and supply chain security markets.
Applied DNA Sciences, Inc. (NASDAQ: APDN) announced a public offering of 3 million shares of common stock at $4.00 per share, along with two series of warrants. The gross proceeds from this offering are expected to reach $12 million, earmarked for the development of Therapeutic DNA Production and MDx Testing Services, among other corporate purposes. The offering is expected to close around August 8, 2022, subject to customary conditions. H.C. Wainwright & Co. acts as the exclusive placement agent for the offering.
Applied DNA Sciences (NASDAQ: APDN) announced its clinical lab subsidiary, Applied DNA Clinical Labs (ADCL), is validating a PCR-based monkeypox virus test. This test aims to detect the A17L gene specific to monkeypox, differentiating it from other orthopoxviruses. Upon validation, the test will be submitted to the New York State Department of Health for approval and utilized in ADCL's testing services. ADCL plans to leverage its established COVID-19 workflows to ensure efficiency and accuracy in monkeypox testing, enhancing public health response capabilities.
Applied DNA Sciences (NASDAQ: APDN) announced a manuscript publication demonstrating that its LinearDNA vaccine elicited neutralizing antibodies against SARS-CoV-2 in domestic cats. Developed by its subsidiary LineaRx in collaboration with EvviVax, the vaccine showed promising safety and immunogenicity. Additionally, the successful expression of the linDNA vaccine encapsulated in lipid nanoparticles (LNP) was confirmed, paving the way for future animal studies. The company is also exploring out-licensing opportunities for its canine lymphoma vaccine candidate, contingent on successful clinical trials and regulatory approvals.
Applied DNA Sciences (NASDAQ: APDN) announced that Dr. James A. Hayward will present on the benefits of linearDNA as a template for mRNA production at the mRNA-Based Therapeutics Summit in Boston from July 26-28, 2022. His presentation, titled ‘The Future of RNA Therapies Produced from LinearDNA™ Templates,’ is set for July 27 at 4:30 PM EST. The linearDNA method offers advantages over traditional plasmid DNA, including a simplified workflow, less DNA requirement for RNA yields, and removal of problematic sequences. Visit linearxdna.com for more details.
Applied DNA Sciences (NASDAQ: APDN) has launched business development initiatives to promote its LinearDNA™ platform, a cell-free enzymatic DNA production method aimed at enhancing the biotherapeutics sector's efficiency. The company, through its subsidiary LineaRx, is advocating LinearDNA as a viable alternative to traditional plasmid-based DNA production, claiming advantages in speed, purity, flexibility, and scalability. Key applications include DNA vaccines, mRNA production, and gene therapy manufacturing, with preclinical studies showing linDNA's effectiveness.
Applied DNA Sciences (NASDAQ: APDN) is advancing its CertainT® platform as a U.S.-made solution to demonstrate goods’ origins, adhering to the Uyghur Forced Labor Prevention Act (UFLPA) effective from June 21, 2022. The UFLPA bans imports from China's Xinjiang region due to forced labor concerns. The Department of Homeland Security recognizes DNA traceability and isotopic testing as methods to prove compliance. With a focus on securing global supply chains, Applied DNA aims for industry adoption of its technology, which has significant implications for cotton sourcing and overall supply chain security.
Applied DNA Sciences (NASDAQ: APDN) has announced the initiation of its first canine clinical trial for a lymphoma cancer vaccine, based on a peer-reviewed study published in The Journal of Experimental & Clinical Cancer Research. This study supports the use of the company’s LinearDNA™ platform, demonstrating promising preclinical data indicating a strong immune response in canine models. The vaccine targets B-cell lymphoma, the most common cancer in dogs, with plans for a trial to begin this year. This innovation could lead to a conditional license application with the USDA.
FAQ
What is the current stock price of Applied DNA Sciences (APDN)?
What is the market cap of Applied DNA Sciences (APDN)?
What services does Applied DNA Sciences provide?
What is the Linea™ IVT platform?
How does Applied DNA contribute to supply chain security?
What was the purpose of the recent public offering by Applied DNA?
What recent patent has Applied DNA received?
What is the significance of the reverse stock split?
Which markets does Applied DNA Sciences primarily serve?
How does Applied DNA's technology benefit mRNA vaccine production?
What recent collaborations has Applied DNA announced?
Where can investors find more information about Applied DNA?
